(Q37728765)

22 August 2017

1 reference

title

Targeted therapy in breast cancer: current status and future directions (English)

1 reference

22 August 2017

Hirofumi Mukai

1

1 reference

22 August 2017

publication date

8 April 2010

1 reference

Japanese Journal of Clinical Oncology

22 August 2017

published in

1 reference

22 August 2017

volume

40

1 reference

22 August 2017

issue

8

1 reference

22 August 2017

page(s)

711-716

1 reference

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ037

Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ037

Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ037

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ037

Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ037

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ037

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ037

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ037

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ037

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ037

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ037

Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ037

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ037

A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ037

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ037

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ037

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ037

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ037

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ037

Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ037

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ037

Receptor tyrosine kinases: mechanisms of activation and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ037

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ037

The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ037

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ037

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ037

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ037

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ037

Targeted therapy for cancer using PARP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ037

21 January 2018

Identifiers

DOI

10.1093/JJCO/HYQ037

1 reference

22 August 2017

1 reference